Clinical trials: Untreated, open to volunteers
Hodgkin Lymphoma
A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India
The main aim of this study is to check how safe brentuximab vedotin is in adults with untreated Hodgkin Lymphoma (HL) when given together with doxorubicin (Adriamycin), vinblastine and dacarbazine therapy ('AVD').
- Trial name
- NCT06831370
- Testing
- Brentuximab Vedotin, Doxorubicin, Vinblastine
- Where
- 11 sites in India
- Volunteers
- 124 people
- Sponsor
- Takeda
LCA5
Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients
The goals of this clinical trial are assess the natural course of LCA5-IRD over 6 months and to evaluate the safety and preliminary efficacy of subretinal gene therapy with OPGx-001 in patients with inherited retinal degeneration…
- Trial name
- NCT05616793
- Testing
- AAV8.hLCA5
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Opus Genetics, Inc
Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma (UC)
A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma
A Randomized, Open-Label, Multicenter, Phase 2/3 Clinical Study of Ivonescimab in Combination with Enfortumab Vedotin vs Pembrolizumab in Combination with Enfortumab Vedotin in Previously Untreated Locally Advanced or Metastatic…
- Trial name
- HARMONi-GU1 (NCT07815665)
- Testing
- Ivonescimab Dose 1, enfortumab vedotin (EV), Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 800 people
- Sponsor
- Summit Therapeutics
Acute Myeloid Leukemia (AML)
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations.
- Trial name
- NCT07007312
- Testing
- Ziftomenib, Venetoclax, Azacitidine (AZA)
- Where
- 136 sites in United States, Australia and 15 more
- Volunteers
- 1,300 people
- Sponsor
- Kura Oncology, Inc.
Colon Cancer
A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer
The goal of this clinical trial is to evaluate the efficacy of neoadjuvant QL1706 in participants with untreated T4N0 or Stage III (resectable), microsatellite instability high/ defective mismatch repair (MSI-H/dMMR) colon cancer
- Trial name
- NCT06686576
- Testing
- QL1706, CAPEOX/Capecitabine
- Where
- China
- Volunteers
- 363 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Extensive-stage Small-cell Lung Cancer
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for…
- Trial name
- NCT06712355
- Testing
- Pumitamig, Atezolizumab, Etoposide
- Where
- 225 sites in United States, Australia and 12 more
- Volunteers
- 621 people
- Sponsor
- BioNTech SE
Prostate Cancer
Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer
The goal of this clinical trial is to test if the experimental agent accurately determines the aggressiveness of prostate cancer (biopsy-verified ISUP grade).
- Trial name
- uTRACE-101 (NCT06474806)
- Testing
- 64Cu-DOTA-AE105
- Where
- 9 sites in Denmark, Germany and 1 more
- Volunteers
- 168 people
- Sponsor
- Curasight
NSCLC (Advanced Non-small Cell Lung Cancer)
A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This is a randomized, open-label, multicenter phase III study to evaluate the efficacy and safety of JYP0322 compared with crizotinib in previously untreated ROS1-positive locally advanced or metastatic non-small cell lung cancer.
- Trial name
- NCT07816380
- Testing
- JYP0322 Tablets, Crizotinib Capsules
- Volunteers
- 216 people
- Sponsor
- Guangzhou JOYO Pharma Co., Ltd
Chronic Lymphocytic Leukemia
PICAROS - Acalabrutinib RWE on 1L CLL in Spain
This is a multicenter non-interventional study (NIS) of patients with CLL treated with first-line acalabrutinib according to routine clinical practice in Spain.
- Trial name
- PICAROS (NCT05999877)
- Where
- 50 sites in Spain
- Volunteers
- 315 people
- Sponsor
- AstraZeneca
Untreated Follicular Lymphoma
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3…
- Trial name
- NCT06549595
- Testing
- Surovatamig, R-CHOP, R-CVP
- Where
- 244 sites in United States, Australia and 23 more
- Volunteers
- 1,018 people
- Sponsor
- AstraZeneca
Follicular Lymphoma (FL)
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL).
- Trial name
- OLYMPIA-1 (NCT06091254)
- Testing
- Odronextamab, Rituximab, Cyclophosphamide
- Where
- 190 sites in United States, Australia and 17 more
- Volunteers
- 822 people
- Sponsor
- Regeneron Pharmaceuticals
Triple Negative Breast Cancer
to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)
This study is a randomized, double-Blind,international multi-Centre, phase III clinical study to evaluate efficacy and safety of HLX10 in combination with chemotherapy versus placebo in combination with chemotherapy as…
- Trial name
- NCT04301739
- Testing
- HLX10, nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide
- Volunteers
- 522 people
- Sponsor
- Shanghai Henlius Biotech
Haemophilia A
Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.
This is an Open Label, Uncontrolled Study to Evaluate the the Safety and Efficacy of SCT800 for Prophylaxis Treatment in Severe Previously Untreated Hemophilia Patients.
- Trial name
- NCT07437404
- Testing
- SCT800 prophylaxis and treatment for bleeding events
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sinocelltech Ltd.
Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations.
- Conditions
- Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation, Refractory AML, AML With Mutated NPM1
- Trial name
- NCT05735184
- Testing
- Ziftomenib, Venetoclax, Azacitidine
- Where
- 44 sites in United States
- Volunteers
- 420 people
- Sponsor
- Kura Oncology, Inc.
Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations
Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations
To evaluate the efficacy and safety of RC148 plus platinum-based chemotherapy versus tislelizumab plus platinum-based chemotherapy in trial participants with previously untreated locally advanced (Stage IIIB/IIIC) or metastatic…
- Trial name
- NCT07829549
- Testing
- RC148 Injection plus Pemetrexed Disodium for Injection and Carboplatin Injection, Tislelizumab Injection plus Pemetrexed Disodium for Injection and Carboplatin Injection
- Where
- China
- Volunteers
- 540 people
- Sponsor
- RemeGen Co., Ltd.
Advanced Solid Tumor, Non Small Cell Lung Cancer
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC, 1st Line NSCLC
- Trial name
- SYNERGY-101 (NCT05098132)
- Testing
- STK-012, pembrolizumab KEYTRUDA®, pemetrexed
- Where
- 60 sites in United States, Georgia and 4 more
- Volunteers
- 364 people
- Sponsor
- Synthekine
Parkinson's Disease (PD)
A Phase 2 Study to Assess the Effects of SUL-238 on High Energy Phosphates With ³¹P-MRS in Patients With Early, Untreated Parkinson's Disease
The main goal of the study is to investigate how well the new drug SUL-238 works in Parkinson's Disease (PD). This is done by means of an MRS scan. An MRS scan is similar to a regular MRI scan.
- Trial name
- SHEPHERD (NCT07322887)
- Testing
- SUL-238 (1500 mg t.i.d.) film-coated tablets, SUL-238 (500 mg t.i.d.) film-coated tablets
- Where
- Netherlands
- Volunteers
- 45 people
- Sponsor
- GEN İlaç ve Sağlık Ürünleri A.Ş.
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread.
- Conditions
- Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
- Trial name
- FORAGER-2 (NCT07218380)
- Testing
- Vepugratinib, EV, Pembrolizumab
- Where
- 276 sites in United States, Australia and 17 more
- Volunteers
- 450 people
- Sponsor
- Eli Lilly and Company
Triple-Negative Breast Cancer (TNBC)
A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)
This trial is a registrational Phase III, randomized, open-label, multicenter study designed to compare the efficacy and safety of BL-B01D1 in combination with a PD-1 monoclonal antibody versus nab-paclitaxel in combination with…
- Trial name
- NCT07729956
- Testing
- BL-B01D1, PD-1 monoclonal antibody, Nab-paclitaxel
- Where
- China
- Volunteers
- 436 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Diffuse Large B-Cell Lymphoma
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
The study will measure the safety, tolerability, and efficacy with acalabrutinib in combination with rituximab in treatment-naïve elderly and/or frail patients with diffuse large B-cell lymphoma (DLBCL), who are otherwise…
- Trial name
- ACRUE (NCT05952024)
- Testing
- Acalabrutinib, Rituximab
- Where
- 57 sites in United States, Brazil and 3 more
- Volunteers
- 80 people
- Sponsor
- AstraZeneca